NO in Early Pregnancy and Development of Preeclampsia
2006; Lippincott Williams & Wilkins; Volume: 47; Issue: 4 Linguagem: Inglês
10.1161/01.hyp.0000205226.01641.fe
ISSN1524-4563
AutoresEnrique Terán, Carlos Escudero, Sandra Vivero, Gustavo Otoboni Molina, Andrés Calle,
Tópico(s)Pregnancy and Medication Impact
ResumoHomeHypertensionVol. 47, No. 4NO in Early Pregnancy and Development of Preeclampsia Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBNO in Early Pregnancy and Development of Preeclampsia Enrique Teran, Carlos Escudero and Sandra Vivero Gustavo Molina and Andres Calle Enrique TeranEnrique Teran Experimental Pharmacology and Cellular Metabolism Unit, Biomedical Center, Central University, Quito, Ecuador , Carlos EscuderoCarlos Escudero Experimental Pharmacology and Cellular Metabolism Unit, Biomedical Center, Central University, Quito, Ecuador and Sandra ViveroSandra Vivero Experimental Pharmacology and Cellular Metabolism Unit, Biomedical Center, Central University, Quito, Ecuador Gustavo MolinaGustavo Molina Hospital Gineco-Obstetrico Isidro Ayora, Quito, Ecuador and Andres CalleAndres Calle Hospital Gineco-Obstetrico Isidro Ayora, Quito, Ecuador Originally published13 Feb 2006https://doi.org/10.1161/01.HYP.0000205226.01641.feHypertension. 2006;47:e17Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 13, 2006: Previous Version 1 To the Editor:We read with interest the article published by Khan et al.1 Between April 2001 and November 2002 we conducted a prospective study approved by the Bioethics Committee.2,3 There were included 68 healthy pregnant women, primigravidae, younger than 25 years, and attending the Hospital Gineco Obstetrico Isidro Ayora in Quito, Ecuador. All women were included at 16 weeks of gestation and were evaluated every 4 weeks until week 36, after then every 2 weeks up to delivery. Onset of preeclampsia was defined as a blood pressure >140/90 mm Hg on at least 2 occasions more than 6 hours apart and proteinuria greater than 300 mg/dL. In every control a blood sample was taken and immediately transferred into a vial containing 3.15% sodium citrate (1:9 v/v) and gently mixed by inversion. Samples taken at delivery were obtained before labor activity was present. NO was quantified using a chemioluminicence system (NOA 280, Sievers System) as reported.4 Preeclampsia was found in 13.3% (n=9) of all studied women. Concentrations of NO were different in women with normal pregnancy (P=0.009), but not in women who developed preeclampsia. During normal pregnancy, NO concentrations at week 16 (29 standard error mean [SEM] 3.6 μmol/L) decreased at week 20 (21.1 SEM 1.7 μmol/L; P=0.04) and week 24 (18.7 SEM 1.7 μmol/L; P=0.01). However, at week 28, there was a slight increase (23.2 SEM 2 μmol/L), followed by a decline at week 32 (19.3 SEM 1.5 μmol/L, P=0.04 versus week 16). From then to delivery, there was a progressive increase in NO concentrations at week 36 (22.2 SEM 1.5 μmol/L) and week 38 (28.2 SEM 4.2 μmol/L; P=0.04 versus week 32). Interestingly, NO concentrations at 38 weeks and at delivery (28.8 SEM 3.7 μmol/L) were no different from those at 16 weeks. However, in women with preeclampsia, NO concentrations at week 16 (13.8 SEM 1.3 μmol/L) were lower than those obtained at week 20 (19.3 SEM 2.5 μmol/L; P=0.06). At week 24 there was a decline in NO concentrations (14.6 SEM 2.6); this reached its maximum level at week 28 (23.4 SEM 3.7 μmol/L; P=0.06 versus week 24 and P=0.02 versus week 16). From then, NO concentrations decreased at week 32 (17 SEM 1.2 μmol/L) and remained with no change until delivery (19.3 SEM 1.2 at week 36). NO concentrations were higher in normal pregnancy compared with preeclampsia at week 16 (P=0.006) and delivery (P=0.04). Using a cutoff NO concentration at week 16 of 13.25 μmol/L, the relative risk for future onset of preeclampsia was 13.33 (95% confidence interval 1.82 to 97.82), with a sensitivity of 80% and a specificity of 90%. Also, the test showed a positive predictive value of 66.7% and a negative predictive value of 95%, with a likelihood ratio of 8.4. This constitutes the first followup study of NO in women with normal pregnancy and in those who develop preeclampsia.Financial support provided by the Sustainable Science Institute (SSI). E.T. was granted with a PhD studentship by Fundacion para la Ciencia y Tecnologia-Ecuador.1 Khan F, Belch JJF, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension. 2005; 46: 1123–1128.LinkGoogle Scholar2 Teran E, Escudero C, Calle A. Seroprevalence of antibodies to chlamydia pneumoniae in women with preeclampsia. Obstet Gynecol. 2003; 102: 198–199.MedlineGoogle Scholar3 Teran E, Escudero C, Calle A. C-reactive protein during normal pregnancy and preeclampsia. Int J Gynecol Obstet. 2005; 89: 299–300.CrossrefMedlineGoogle Scholar4 Teran E, Escudero C, Vivero S. Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide. 2002; 7: 217–220.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Caldeira-Dias M, Montenegro M, Bettiol H, Barbieri M, Cardoso V, Cavalli R and Sandrim V (2019) Resveratrol improves endothelial cell markers impaired by plasma incubation from women who subsequently develop preeclampsia, Hypertension Research, 10.1038/s41440-019-0243-5, 42:8, (1166-1174), Online publication date: 1-Aug-2019. Giachini F, Galaviz-Hernandez C, Damiano A, Viana M, Cadavid A, Asturizaga P, Teran E, Clapes S, Alcala M, Bueno J, Calderón-Domínguez M, Ramos M, Lima V, Sosa-Macias M, Martinez N, Roberts J and Escudero C (2017) Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries, Current Hypertension Reports, 10.1007/s11906-017-0781-7, 19:10, Online publication date: 1-Oct-2017. Littarru G, Bruge F and Tiano L (2017) Biochemistry of Coenzyme Q10 Antioxidants in Andrology, 10.1007/978-3-319-41749-3_2, (23-34), . Mazzanti L, Raffaelli F, Vignini A, Nanetti L, Vitali P, Boscarato V, Giannubilo S and Tranquilli A (2011) Nitric oxide and peroxynitrite platelet levels in gestational hypertension and preeclampsia, Platelets, 10.3109/09537104.2011.589543, 23:1, (26-35), Online publication date: 1-Feb-2012. Littarru G and Tiano L (2010) Clinical aspects of coenzyme Q10: An update, Nutrition, 10.1016/j.nut.2009.08.008, 26:3, (250-254), Online publication date: 1-Mar-2010. Teran E, Hernandez I, Nieto B, Tavara R, Ocampo J and Calle A (2009) Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia, International Journal of Gynecology & Obstetrics, 10.1016/j.ijgo.2008.11.033, 105:1, (43-45), Online publication date: 1-Apr-2009. Teran E, Chedraui P, Vivero S, Villena F, Duchicela F and Nacevilla L (2008) Plasma and placental nitric oxide levels in women with and without pre-eclampsia living at different altitudes, International Journal of Gynecology & Obstetrics, 10.1016/j.ijgo.2008.09.010, 104:2, (140-142), Online publication date: 1-Feb-2009. Chen D, Wang H, Huang H and Dong M (2009) Vascular Endothelial Growth Factor Attenuates Nω-Nitro-L-Arginine Methyl Ester-Induced Preeclampsia-Like Manifestations in Rats, Clinical and Experimental Hypertension, 10.1080/10641960802443118, 30:7, (606-615), Online publication date: 1-Jan-2008. April 2006Vol 47, Issue 4 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.0000205226.01641.fePMID: 16476864 Originally publishedFebruary 13, 2006 PDF download Advertisement
Referência(s)